Instruction for use: Etodolac (Etodolacum)

Pharmacological group

NSAIDs - Derivatives of acetic acid and related compounds

Nosological classification (ICD-10)

M06.9 Other specified rheumatoid arthritis

Rheumatoid arthritis,Pain syndrome in rheumatic diseases, Pain in rheumatoid arthritis, Inflammation in rheumatoid arthritis, Degenerative forms of rheumatoid arthritis, Children's rheumatoid arthritis, Exacerbation of rheumatoid arthritis, Acute articular rheumatism, Rheumatic arthritis, Rheumatic polyarthritis, Rheumatoid arthritis, Rheumatic polyarthritis, Rheumatoid arthritis, Rheumatoid arthritis of active course, Rheumatoid arthritis, Rheumatoid polyarthritis, Acute rheumatoid arthritis, Acute rheumatism

M10 Gout

Exacerbation of gout, Acute articular attack with gout, Acute gouty attack, Gouty attack, Recurrent gout attacks, Chronic gout

M13.9 Arthritis, unspecified

Arthritis,Purulent arthritis (non-infectious), acute Arthritis,Pain in acute inflammatory diseases of the musculoskeletal system,Pain in chronic inflammatory diseases of the musculoskeletal system,The pain in osteoarthritis, Inflammation in osteoarthritis, Inflammatory arthropathy, Inflammatory and degenerative joint diseases, Inflammatory disease of the musculoskeletal system, Inflammatory joint disease, Inflammatory diseases of the musculoskeletal system, destructive arthritis, The disease of the musculoskeletal system, Diseases of the musculoskeletal system, Diseases of the musculoskeletal system and connective tissue, Infections musculoskeletal system, monoartrit, Non-infectious arthritis, rheumatic arthritis, Osteoarthritis, Acute inflammation of the musculoskeletal tissue, Acute inflammatory diseases of the musculoskeletal system, Acute inflammatory condition of the musculoskeletal system, Acute arthritis, Acute osteoarthritis, Post-traumatic osteoarthritis, Reactive arthritis, Chronic inflammatory diseases of the joints, Chronic arthritis, Chronic inflammatory arthritis, Chronic inflammation of the inner layer of the joint capsule, Chronic inflammation of the joint capsule,Chronic inflammatory disease of the joints, Exudative arthritis

M15-M19 Osteoarthritis

M45 Ankylosing spondylitis

Ankylosing spondylarthrosis, Marie-Strumpel disease, Ankylosing spondylitis, Pain syndrome in acute inflammatory diseases of the musculoskeletal system, Pain syndrome in chronic inflammatory diseases of the musculoskeletal system, Bechterew's disease, Ankylosing spondylitis, Diseases of the spinal column, Rheumatic spondylitis, Bechterew-Marie-Strumpel disease

M79.0 Other unspecified rheumatism

Degenerative rheumatic disease, Degenerative and rheumatic diseases of the tendons, Degenerative rheumatic diseases, Localized forms of rheumatism of soft tissues, Rheumatism, Rheumatism with a pronounced allergic component, Rheumatism of the articular and extraarticular, Rheumatic attack, Rheumatic complaints, Rheumatic diseases, Rheumatic disease of the spine, Relapses of rheumatism, Articular and extra-articular rheumatism, Articular and muscular rheumatism, Articular rheumatism, Articular syndrome with rheumatism, Chronic rheumatic pain, Chronic articular rheumatism, Rheumatoid diseases, Rheumatic diseases of the intervertebral disc

R52.2 Other constant pain

Pain syndrome, rheumatic origin, Pain at vertebral lesions, Pain in the chamber, Pain for burns, Pain syndrome weak or moderate, Perioperative pain,Moderate to severe pain, Moderately or weakly expressed pain syndrome, Moderate to severe pain, Ear pain of otitis, Neuropathic pain, neuropathic pain

Code CAS 41340-25-4

Characteristics of Etodolac

White crystalline powder, insoluble in water, soluble in alcohols, chloroform and dimethylsulfoxide, an aqueous solution of polyethylene glycol. Molecular weight 287.37.

Pharmacology

Pharmacological action - anti-inflammatory, antipyretic, analgesic.

Inhibits cyclooxygenase, inhibits the synthesis of PG (prostaglandins).

Quickly and completely absorbed from the digestive tract (gastrointestinal tract). Cmax is achieved in 50-110 minutes. Binding to plasma proteins is 99%, mainly with albumin. Plasma Cl is 30-55 ml / h / kg. T1 / 2 - 3,5-10 hours Biotransformiruetsya in the liver. Only 1% is excreted unchanged in the urine, the rest in the form of metabolites: 13% - glucuronides, 29% - hydroxylated and 33% - unidentified derivatives.

use of Etodolac

Rheumatism, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, pain syndrome.

Update of information

Inflammatory and degenerative diseases of the musculoskeletal system: psoriatic, rheumatoid, gouty arthritis, ankylosing spondylitis (Bechterew's disease), osteoarthritis.

Pain syndrome: myalgia, ossalgia, arthralgia, headache and toothache, posttraumatic pain syndrome, accompanied by inflammation, algodismenorea.

It is intended for symptomatic therapy, reducing pain and inflammation at the time of use, the progression of the disease is not affected.

Contraindications

Hypersensitivity, bleeding in the digestive tract (gastrointestinal tract), peptic ulcer of the stomach and duodenum, pregnancy, breast-feeding, children's age.

pregnancy and lactation

The action category for fetus by FDA is C.

At the time of treatment, breastfeeding should be discontinued (it is not known whether etodolac is excreted into breast milk).

Side effects

Dyspeptic phenomena, ulceration of the stomach mucosa, nausea, vomiting, headache, dizziness, bronchospasm, dysuric disorders, hyperpigmentation, leukopenia, anemia, thrombocytopenia, erythema multiforme, rash, itching.

Interaction

Antacids can reduce Cmax (by 15-20%). Acetylsalicylic acid and warfarin reduce binding (competition) with plasma proteins.

Overdose

Symptoms: nausea, vomiting, pain in the epigastric region, arterial hypertension, anaphylactic reactions.

Routes of administration

Inside.

Precautions for Etodolac

It should be noted that etodolak (especially with prolonged use) increases the risk of developing gastric and duodenal ulcers, bleeding and perforation of the gastrointestinal tract, necrosis of the renal epithelium.